Point72 Asset Management
ALLO icon

Point72 Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Point72 Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$540K Buy
221,335
+117,595
+113% +$236K ﹤0.01% 3086
2025
Q4 		$142K Buy
+103,740
New +$137K ﹤0.01% 3696
2024
Q1 		– Sell
-679,468
Closed -$2.18M – 2141
2023
Q4 		$2.18M Buy
+679,468
New +$1.93M 0.01% 1175
2023
Q3 		– Sell
-2,217
Closed -$11K – 2425
2023
Q2 		$11K Buy
2,217
+119
+6% +$644 ﹤0.01% 1901
2023
Q1 		$10.4K Buy
+2,098
New +$13.5K ﹤0.01% 2035
2022
Q4 		– Sell
-293,200
Closed -$3.17M – 1493
2022
Q3 		$3.17M Buy
+293,200
New +$3.98M 0.01% 834

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return